Head to Head Analysis: Bonk (BNKK) vs. The Competition
by Michael Walen · The Markets DailyBonk (NASDAQ:BNKK – Get Free Report) is one of 344 publicly-traded companies in the “Financial Services” industry, but how does it weigh in compared to its competitors? We will compare Bonk to related businesses based on the strength of its dividends, valuation, profitability, risk, institutional ownership, analyst recommendations and earnings.
Valuation & Earnings
This table compares Bonk and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Bonk | $2.12 million | -$68.19 million | -0.37 |
| Bonk Competitors | $6.73 billion | $1.09 billion | 9.25 |
Bonk’s competitors have higher revenue and earnings than Bonk. Bonk is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares Bonk and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bonk | -952.21% | -137.47% | -122.67% |
| Bonk Competitors | -407.45% | -22.01% | -5.65% |
Institutional & Insider Ownership
12.6% of Bonk shares are held by institutional investors. Comparatively, 43.2% of shares of all “Financial Services” companies are held by institutional investors. 51.6% of Bonk shares are held by insiders. Comparatively, 21.9% of shares of all “Financial Services” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk & Volatility
Bonk has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500. Comparatively, Bonk’s competitors have a beta of 2.26, indicating that their average share price is 126% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and price targets for Bonk and its competitors, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bonk | 1 | 0 | 0 | 0 | 1.00 |
| Bonk Competitors | 1891 | 6816 | 11538 | 414 | 2.51 |
As a group, “Financial Services” companies have a potential upside of 3.86%. Given Bonk’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Bonk has less favorable growth aspects than its competitors.
Summary
Bonk competitors beat Bonk on 12 of the 13 factors compared.
About Bonk
Safety Shot, Inc., a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as Jupiter Wellness, Inc. and changed its name to Safety Shot, Inc. in September 2023. The company was incorporated in 2018 and is headquartered in Jupiter, Florida.